Usein Codruţa-Romaniţa, Condei Maria, Cristea Dana, Ciontea Simona Adriana, Tatu-Chiţoiu Dorina, Cristea Violeta, Străuţ Monica
Roum Arch Microbiol Immunol. 2014 Jan-Jun;73(1-2):5-8.
Escherichia coli sequence type ST131 is a major pandemic clonal group of drug-resistant extraintestinal pathogenic E. coli (ExPEC) involved in community-onset and healthcare-associated infections. Thus far, its presence in our area has been paid little attention. This is a preliminary study intended to detect ST131 among 87 clinical isolates retrieved from a larger and unpublished E. coli collection. The study isolates originated from various specimens associated with invasive infections (blood, deep surgical wounds/abscesses, tracheal aspirates, pleural fluid, cerebrospinal fluid, and peritoneal fluid) and were collected between 2010 and 2014. Based on the main inclusion criteria, resistance to extended-spectrum cephalosporins (ESCs) and/or fluoroquinolones (FQs), the isolates were distributed in three categories: isolates with resistance to FQs (20 isolates), to ESCs (8 isolates), and to FQs and ESCs (59 isolates), respectively. Polymerase chain reaction (PCR) -based assays were performed to determine the major phylogenetic groups, to predict the MLST ST131 status, and to detect the bla(CTX-M) content of the ESC-resistant isolates. Overall, the studied isolates derived from phylogenetic groups B2 (42 isolates), A (30 isolates), B1 (11 isolates), and D (4 isolates). Thirty-five isolates, originating from blood (26 isolates), deep wounds (6 isolates), tracheal aspirates (2 isolates), and cerebrospinal fluid (1 isolate), were identified as members of O25b:H4 ST131. Most of them displayed resistance to both ESCs and FQs and harboured group 1 bla(CRX-M) genes. The emergence of ST131 in our region can no longer be ignored. Focused attention to this lineage could reduce infection-related morbidity and antibiotic resistance.
大肠埃希菌序列类型ST131是耐药性肠外致病性大肠埃希菌（ExPEC）的一个主要大流行克隆群，涉及社区获得性感染和医疗保健相关感染。到目前为止，我们地区对其存在情况关注甚少。这是一项初步研究，旨在从一个更大的未发表的大肠埃希菌菌株库中检索的87株临床分离株中检测ST131。研究分离株来自与侵袭性感染相关的各种标本（血液、深部手术伤口/脓肿、气管吸出物、胸腔积液、脑脊液和腹腔积液），收集时间为2010年至2014年。根据主要纳入标准，即对超广谱头孢菌素（ESCs）和/或氟喹诺酮类（FQs）耐药，这些分离株分为三类：对FQs耐药的分离株（20株）、对ESCs耐药的分离株（8株）和对FQs和ESCs耐药的分离株（59株）。进行基于聚合酶链反应（PCR）的检测，以确定主要系统发育群、预测MLST ST131状态，并检测ESCs耐药分离株的bla(CTX-M)含量。总体而言，所研究的分离株来自系统发育群B2（42株）、A（30株）、B1（11株）和D（4株）。35株分离株，分别来自血液（26株）、深部伤口（6株）、气管吸出物（2株）和脑脊液（1株），被鉴定为O25b:H4 ST131成员。其中大多数对ESCs和FQs均耐药，并携带1组bla(CRX-M)基因。ST131在我们地区的出现已不容忽视。对这一谱系给予重点关注可降低感染相关的发病率和抗生素耐药性。
